Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events


Acquired byCephalon
TermsCash and Stock

General Information


Montreal, CAN
3576 Avenue du Parc
Suite 4310, QC
Montreal, H2X 2H7, CAN


Chief Financial Officer
Chairman and Chief Executive Officer
Chief Scientific Officer and Co-founder
Executive Vice President and Chief Medical Officer



Gemin X Pharmaceuticals

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.

Gemin X’s research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.

Recent Milestones



Gemin X Pharmaceuticals screenshot
Above: Gemin X Pharmaceuticals
Uploaded: 3/11/10


  1. Cephalon Announces Definitive Agreement to Acquire Gemin X ( [edit]
  2. Gemin X Pharmaceuticals closes $38 Mn Series C financing ( [edit]
  3. SEC ( [edit]
  4. Gemin X books $16M Series D as it pursues PhIIb cancer trial Read more: ( [edit]
  5. Gemin X Pharmaceuticals, Inc.: Series E $8M ( [edit]
Edit This Page
Last Edited 2/25/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy